Cargando…
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes. DESIGN: Cohort study. SETTING: US Department of Veterans Affairs. PARTICIPANTS: 229 286 participants...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126525/ https://www.ncbi.nlm.nih.gov/pubmed/37161995 http://dx.doi.org/10.1136/bmj-2022-074572 |